{"organizations": [], "uuid": "ba5d50c59d43310e2b2a5a9500c9ecc0d12ba26c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-portola-pharmaceuticals-q4-loss-pe/brief-portola-pharmaceuticals-q4-loss-per-share-1-41-idUSASB0C82Z", "country": "US", "domain_rank": 408, "title": "BRIEF-Portola Pharmaceuticals Q4 Loss Per Share $1.41", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-28T23:36:00.000+02:00", "replies_count": 0, "uuid": "ba5d50c59d43310e2b2a5a9500c9ecc0d12ba26c"}, "author": "", "url": "https://www.reuters.com/article/brief-portola-pharmaceuticals-q4-loss-pe/brief-portola-pharmaceuticals-q4-loss-per-share-1-41-idUSASB0C82Z", "ord_in_thread": 0, "title": "BRIEF-Portola Pharmaceuticals Q4 Loss Per Share $1.41", "locations": [], "entities": {"persons": [], "locations": [{"name": "portola", "sentiment": "none"}], "organizations": [{"name": "brief-portola pharmaceuticals", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "portola pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 37 PM / Updated 9 minutes ago BRIEF-Portola Pharmaceuticals Q4 Loss Per Share $1.41 Reuters Staff Feb 28 (Reuters) - Portola Pharmaceuticals Inc: * PORTOLA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE * Q4 LOSS PER SHARE $1.41 * FOR FISCAL YEAR 2018, PORTOLA EXPECTS TOTAL GAAP OPERATING EXPENSES TO BE BETWEEN $390 MILLION AND $430 MILLION * QTRLY COLLABORATION AND LICENSE REVENUE $9.8 MILLION VERSUS $13.7 MILLION * Q4 EARNINGS PER SHARE VIEW $-1.46 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-28T23:36:00.000+02:00", "crawled": "2018-02-28T23:51:45.016+02:00", "highlightTitle": ""}